Introduction {#S0001}
============

Esophageal cancer (EC) is the sixth major cause of cancer-related death globally, and esophageal squamous cell carcinoma (ESCC) is the predominant pathological subtype worldwide.[@CIT0001],[@CIT0002] Above half of all diagnosed EC cases occurred in Asian countries and the five-year survival rates for the patients with this disease are still low and unsatisfactory.[@CIT0003],[@CIT0004] Prognosis-related indicators could contribute to prognostic assessment as well as individualized treatment. Thus, searching for prognostic indicators that are non-invasive and easily-available is significant and required for clinical practice.

Increasing evidence has shown systemic inflammatory responses and nutritional status were involved in tumor development and considered as important factors associated with clinical prognosis in various types of cancers.[@CIT0005]--[@CIT0008] And therefore a series of biological indicators based on inflammatory and/or nutritional status have been reported as tumor biomarkers.[@CIT0009]--[@CIT0011] Among them, systemic immune-inflammation index (SII), defined as neutrophil × platelet/lymphocyte, was initially known as an indicator of the host inflammatory status as well as a prognostic marker in hepatocellular carcinoma.[@CIT0012] And the good prognostic value of SII was subsequently reported in EC and other tumors.[@CIT0013],[@CIT0014] Another inflammation-based score, C-reactive protein-to-albumin ratio (CAR), based on C-reactive protein and albumin, also aroused great concern in the prediction in multiple tumors, including EC.[@CIT0015]--[@CIT0017] And different cutoffs of these two parameters have been utilized in previous studies to display the predictive values in cancer patients.[@CIT0013]--[@CIT0016]

However, the relationships between pretreatment SII and CAR and clinical outcomes of EC are inconsistent, their values as prognostic tumor markers in EC remain elusive. And to the best of our knowledge, no meta-analysis regarding the clinical significance of both SII and CAR in EC patients is available. Therefore, we searched all relevant literature to perform an integrated meta-analysis to fully address the clinical values of SII and CAR in EC sufferers. According to PICOS principles, the participants with primary EC were included, and we compared the related clinical outcomes in EC patients with high SII/CAR and those with low SII/CAR. Any studies designed that in compliance with screening criteria were considered eligible and collected for further analysis.

Materials and methods {#S0002}
=====================

In this study, we performed the meta-analysis based on the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement.

Search strategy and study selection {#S0002-S2001}
-----------------------------------

Two authors searched eligible articles independently in PubMed, Web of Science, Embase, Cochrane Library databases and Google Scholar from the inception of the databases to September 1, 2018. The search was restricted to the English language. The following keywords and their combinations were used in searching: "carcinoma" or "cancer" or "tumor", and "esophageal", and "systemic immune-inflammation index" or "SII", or "C-reactive protein-to-albumin ratio" or "CAR" or "C-reactive protein/albumin". The detailed search strategy was illustrated in the **Supplementary materials section**. Additionally, the references in the eligible publications were also reviewed for potential studies.

Selection criteria {#S0002-S2002}
------------------

Published articles were included in this meta-analysis if they met the following criteria: 1) All patients collected were histopathologically confirmed to be primary esophageal cancer; 2) The SII and/or CAR were measured prior to treatment; 3) The hazard ratios (HRs) with their 95% confidence interval (95% CI) were reported in multivariate analysis; 4) Original articles were published in English; 5) Only the most complete data were included if overlapping data were found in more than one study. Any studies that were reviews, abstracts, conferences, or posters are excluded in this meta-analysis.

Data extraction {#S0002-S2003}
---------------

For each study, the following information was extracted by two authors: the name of first author, year of publication, country, study type, pathological type, included period, number of patients, age distribution, end-point, follow-up time, cut-off selection, treatments, stage of cancer, cutoff values and HRs with the 95% CIs. Furthermore, the number of patients for the clinical pathology (including tumor grade, infiltration depth, lymph node metastasis, and clinical stage) was directly extracted from the eligible studies.

Quality assessment {#S0002-S2004}
------------------

Two authors independently assessed the quality of each study in the meta-analysis, we used the method that was detailed described in the study by Perisanidis et al[@CIT0018] It contained a total of eight items, and each study included in this meta-analysis could get a final score ranged from 0 to 8 after quality assessment.

Statistical analysis {#S0002-S2005}
--------------------

The risk of bias summary and risk of bias graph were applied using Review Manager 5.3, and the data analyses were performed with STATA/SE 14.1 in this meta-analysis. The cohort-specific HRs and 95% CIs for cancer survival were extracted from multivariate cox proportional hazard models. In addition, subgroup analysis was conducted to explore the prognostic values of SII and CAR in EC patients. And for the associations between SII/CAR and clinicopathologic characteristics in EC cases, the pooled ORs and 95% CIs were evaluated using STATA/SE 14.1. Cochran's Q test and Higgins I square were used to determine the statistical heterogeneity across studies. I^2^\>50% or *P*\<0.1 was considered as heterogeneity, then a random-effects model was used. Otherwise, a fixed-effects model was utilized to combine the data when there was no significant heterogeneity. Publication bias was assessed by Begg's funnel plot and Begg's test. And the sensitivity analysis was utilized by omitting individual study one-by-one to assess the robustness of the results. And *P*-value less than 0.05 was considered statistically significant.

Results {#S0003}
=======

Literature characteristics {#S0003-S2001}
--------------------------

After primary retrieval, a total of 210 relevant articles were incorporated into our initial assessment after exclusion of the duplications, and then 189 articles were further excluded by screening the titles and abstracts. The remaining 21 full-text articles were assessed for eligibility. Among them, 10 articles were further removed with the following reasons: such as HRs were not reported in multivariate analysis, no survival data available, and SII/CAR was measured after treatment. Finally,11 published articles were included in this meta-analysis.[@CIT0014],[@CIT0016],[@CIT0019]--[@CIT0027] Among them, 4 articles were for SII, 6 articles were for CAR, and 1 article was for both SII and CAR. The process of identifying studies is shown in [Figure 1](#F0001){ref-type="fig"}.Figure 1Flow diagram of included studies for this meta-analysis.

For the relationship between SII and survival rate in EC patients, five cohort studies were collected with a total of 2292 cases. Among them, four studies were published in 2017 or later and one study was published before 2017. All these studies assessed patients from East Asian countries (China and Japan), and the endpoints of OS and CSS were addressed in 4 studies and 1 study, respectively, and the CSS was integrated into the meta-analysis of OS. In terms of pathological types, 4 articles reported ESCC, 1 article studied the mixture of ESCC, EAC, and others. The cut-off value of SII varied in different studies, ranging from 307 to 650 with a mean of 462.

For the correction of CAR in EC patients, 7 studies selected for analysis comprised 1742 patients, with sample sizes ranging from 116 to 468 patients. Among them, 2 studies were published in 2015, 2 articles were released in 2017, and 3 studies were published in 2018. 1 study assessed patients from Australia and the rest 6 were conducted in East Asian populations (China and Japan). All the studies assessed the correction of CAR with OS. In terms of pathological types, 5 studies worked on ESCC, 1 studies focused on the mixture of ESCC and EAC, and another one study worked on the mixture of ESCC, EAC, and other types. There was a wide range of the cut-off value of CAR, ranging from 0.023 to 0.95 with the mean of 0.277.

And the relevant data of clinicopathologic characteristics for SII and CAR, including tumor grade, infiltration depth, lymph node metastasis, and clinical stage are shown in [Table S1](#ST0001). The quality of the 12 included cohort studies was good with an average quality score of 7 (range 5--8, [Figure 2](#F0002){ref-type="fig"}, [Table S2](#ST0002)). In addition, the risk of bias summary and risk of bias graph for SII and CAR were presented in [Figures S1](#SF0001) and [Figure S2](#SF0002), respectively. The main characteristics of all cohort studies are summarized in [Table 1](#T0001){ref-type="table"}. Table 1Main characteristics of all included studiesStudy/\
YearPathological typeCountryStudy typeIncluded periodNo. of sampleAge (years)OutcomesFollow-upCutoff valueCut-off selectionTreatment methodsStageMVASIIGeng Y, 2016[@CIT0014]ESCCChinaR2002--2012916median: 60OS≥5 years307X-tile softwareWith-surgeryNon-metastaticYesFeng JF, 2017[@CIT0016]ESCCChinaR2005 −2008298NACSS≥5 years410Cutoff FinderWith-surgeryNon-metastaticYesWang L, 2017[@CIT0019]ESCCChinaR2012.1--2012.12280mean: 64.1OS\<5 years560ROC analysisWith-surgeryMixedYesIshibashi Y, 2018[@CIT0020]ESCC/EAC/OthersJapanR2009--2014143mean: 70.6OS≥5 years650ROC analysisWith-surgeryMixedYesZhang H, 2018[@CIT0021]ESCCChinaR2005 −2013655median: 61OS≥5 years387.65ROC analysisWith-surgeryNon-metastaticYesCARWei XL, 2015[@CIT0022]ESCCChinaR2006--2010423median: 58OS≥5 years0.095ROC analysisMixedMixedYesXu XL, 2015[@CIT0023]ESCCChinaR2000--2010468median: 58OS≥5 years0.5ROC analysisWith-surgeryNon-metastaticYesOtowa Y, 2017[@CIT0024]ESCCJapanR2007--2014149mean: 66.9OS≥5 years0.03ROC analysisWith-surgeryNon-metastaticYesJomrich G, 2017[@CIT0025]ESCC/EACAustriaR2003--2014283mean: 63OS≥5 years0.95NAWith-surgeryMixedYesIshibashi Y, 2018[@CIT0020]ESCC/EAC/OthersJapanR2009--2014143mean: 70.6OS≥5 years0.3ROC analysisWith-surgeryMixedYesKunizaki M, 2018[@CIT0026]ESCCJapanR2007--2014116mean: 66OS≥5 years0.042ROC analysisMixedMixedYesYu X, 2018[@CIT0027]ESCCChinaR2005--2012160median: 59OS≥5 years0.023ROC analysisWith-surgeryNon-metastaticYes[^1] Figure 2Quality assessment of 12 cohort studies included in the meta-analysis according to predefined eight items.Figure S1Risk of bias assessment for SII.**Abbreviations:** SII, systemic immune-inflammation index.Figure S2Risk of bias assessment for CAR.**Abbreviations:** CAR, C-reactive protein-to-albumin ratio.

SII in esophageal cancer {#S0003-S2002}
------------------------

### Overall survival (OS) {#S0003-S2002-S3001}

Five studies with a total of 2292 cases explored the effect of SII on OS in esophageal cancer. As no obvious heterogeneity observed among studies, the fixed effects model was used (I^2^=16.0%, p~het~=0.312). The pooled results indicated that high SII was significantly related with shorter OS in EC patients following surgery (HR: 1.34, 95% CI: 1.15--1.53, *P*\<0.001; [Figure 3](#F0003){ref-type="fig"}).Figure 3Meta-analysis of the correlation between SII and OS.**Abbreviations:** OS, overall survival; SII, systemic immune-inflammation index; HR, hazard ratio; 95%CI, 95% confidence interval.

As shown in [Table 2](#T0002){ref-type="table"}, when stratified by the pathological type, high SII had a significantly worse OS in ESCC (HR: 1.34, 95% CI: 1.14--1.53, *P*\<0.001). In addition, statistically significant pooled multivariable adjusted HR values \>1 were consistently calculated in subgroup meta-analyses stratified by cut-off value (≥462 vs \<462), follow-ups (≥5 years vs \<5 years) and cancer staging (Non-metastatic vs \< Mixed). Table 2Subgroup analysis of the correlation between SII and OSSubgroup factorNo. of studiesPooled HR (95% CI)*P*-valueHeterogeneityI^2^ (%)P~het~**Pathological type** ESCC41.34(1.14--1.53)\<0.00135.10.202 Mixed11.64(0.74--3.96)NS\--**Cut-off value** ≥46222.23(1.26--3.21)\<0.0010.00.367 \<46231.30(1.11--1.50) \<0.0010.00.735**Follow-ups** ≥5 years41.31(1.11--1.50)\<0.0010.00.853 \<5 years12.58(1.62--4.09)\<0.001-**Clinical stage** Non-metastatic31.30(1.11--1.50)\<0.0010.00.735 Mixed22.23(1.26--3.21)\<0.0010.00.367[^2]

### Clinical pathology {#S0003-S2002-S3002}

#### Histological grade {#S0003-S2002-S3002-S4001}

Five articles with 2,292 patients coved the effect of high SII on histological grade. The fixed effect model was used (I^2^=10.0%, P~het~=0.349), the combined results showed that there was no significant difference between SII status and histological grade (OR: 1.07, 95% CI: 0.87--1.30, *P*=0.528; [Figure 4A](#F0004){ref-type="fig"}).Figure 4Meta-analysis of the relationship between SII and clinical pathology in EC patients: **A**) histological grade; **B**) infiltration depth; **C**) lymph node metastasis; **D**) clinical stage.**Abbreviations:** SII, systemic immune-inflammation index; EC, esophageal cancer; OR, odds ratio; 95%CI, 95% confidence interval.

#### Infiltration depth {#S0003-S2002-S3002-S4002}

Four studies, consisting of 1,994 patients, explored the relationship between SII and depth of tumor invasion. The pooled analysis revealed the pooled OR of 2.10 with 95% CI: 1.72--2.56 (*P*\<0.001) ([Figure 4B](#F0004){ref-type="fig"}) with no significant heterogeneity (I^2^=42.4%, P~het~=0.157). Patients with high SII have deeper infiltration depth when compared with those with low SII.

#### Lymph node metastasis {#S0003-S2002-S3002-S4003}

A total of four studies with 1,994 patients reported the relationship between SII and lymph node metastasis. As shown in [Figure 4C](#F0004){ref-type="fig"}, the random effect model was used (I^2^=60.8%, P~het~=0.054), the patients with esophageal cancer were at significantly greater risk of lymph node metastasis (OR: 1.51, 95% CI: 1.09--2.09, *P*\<0.001).

#### Clinical stage {#S0003-S2002-S3002-S4004}

Five studies selected comprised 2,292 patients assessed the association between SII and clinical stage. The estimated proportion of heterogeneity (I^2^) between five SII studies was 50.4% (*P*=0.089), the random effect model was applied. As indicated in [Figure 4D](#F0004){ref-type="fig"}, high SII was correlated with the advanced clinical stage in patients with esophageal cancer (OR: 2.00, 95% CI: 1.51--2.65, *P*\<0.001).

CAR in esophageal cancer {#S0003-S2003}
------------------------

### Overall survival (OS) {#S0003-S2003-S3001}

A total of 1,742 cases from seven articles reported the effect of CAR on OS in esophageal cancer. The fixed effects model was used for no obvious heterogeneity (I^2^=35.7%, P~het~=0.155). The combined results showed that patients with elevated CAR were expected to suffer worse long-term OS (HR: 1.60, 95% CI: 1.29--1.90, *P*\<0.001; [Figure 5](#F0005){ref-type="fig"}).Figure 5Meta-analysis of the correlation between CAR and OS.**Abbreviations:** OS, overall survival; CAR, C-reactive protein-to-albumin ratio; HR, hazard ratio; 95%CI, 95% confidence interval.

As summarized in [Table 3](#T0003){ref-type="table"}, when stratified by the pathological type, CAR could be a significant prognostic biomarker in ESCC (HR: 1.64, 95% CI: 1.30--1.98, *P*\<0.001). In addition, significant associations between high CAR level and poor OS were also found in the subgroup analyses of cut-off value (≥0.277 vs \<0.277), treatments methods (With-surgery vs Mixed) and clinical staging (Non-metastatic vs Mixed). Table 3Subgroup analysis of the correlation between CAR and OSSubgroup factorNo. of studiesPooled HR(95% CI)*P*-valueHeterogeneityI^2^ (%)P~het~**Pathological type** ESCC51.64(1.30--1.98)\<0.00147.80.104 Mixed21.43(0.73--2.12)NS27.50.240**Cut-off value** ≥0.27731.92(1.42--2.42)\<0.00162.30.070 \<0.27741.41(1.02--1.80)\<0.0010.00.668**Treatments** With-surgery51.78(1.33--2.23)\<0.00143.60.131 Mixed21.45(1.03--1.86)\<0.0019.70.293**Clinical stage** Non-metastatic32.04(1.44--2.64)\<0.00150.00.135 Mixed41.44(1.09--1.80)\<0.0010.00.477[^3]

### Clinical pathology {#S0003-S2003-S3002}

#### Histological grade {#S0003-S2003-S3002-S4001}

A total of four articles with 1,193 patients reported the relationship between CAR and histological grade. The pooled results indicated that no significant association was observed between CAR and histological grade (OR: 1.26, 95% CI: 0.69--2.32, *P*=0.456; random-effects; [Figure 6A](#F0006){ref-type="fig"})Figure 6Meta-analysis of the relationship between CAR and clinical pathology in EC patients: (**A**) histological grade; (**B**) infiltration depth; (**C**) lymph node metastasis; (**D**) clinical stage.**Abbreviations:** CAR, C-reactive protein-to-albumin ratio; EC, esophageal cancer; OR, odds ratio; 95%CI, 95% confidence interval.

#### Infiltration depth {#S0003-S2003-S3002-S4002}

Four articles with 1,088 patients reported the correlation between CAR and infiltration depth. As shown in [Figure 6B](#F0006){ref-type="fig"}, significant heterogeneity was observed (I^2^=56.0%, P~het~=0.078; random-effects), the overall results showed that the patients with high CAR more likely to have deeper tumor invasion (OR: 2.42, 95% CI: 1.48--3.98, *P*\<0.001)

#### Lymph node metastasis {#S0003-S2003-S3002-S4003}

Only three articles with 972 cases coved the correlation of high CAR on lymph node metastasis. The fixed effect model was employed (I^2^=21.7%, P~het~=0.279), the combined analysis revealed the pooled OR of 1.83 with 95% CI: 1.34--2.49 (*P*\<0.001) ([Figure 6C](#F0006){ref-type="fig"}), suggesting that high CAR was significantly associated with lymph node metastasis.

#### Clinical stage {#S0003-S2003-S3002-S4004}

Four articles, consisting of 1,150 patients, explored the association between CAR and clinical stage. No obvious heterogeneity was found, the fixed effect model was utilized (I^2^=0.0%, P~het~=0.788). As indicated in [Figure 6D](#F0006){ref-type="fig"}, the patients with high CAR tended to have advanced tumor stages compared those with low CAR (OR: 2.90, 95% CI: 2.20--3.81, *P*\<0.001).

Publication bias {#S0003-S2004}
----------------

The Begg's funnel plots were shown in [Figure 7](#F0007){ref-type="fig"}, and the *P*-values of Begg's were 0.086 for SII and 1.000 for CAR. These results showed that there was no publication bias in the current study. Figure 7Publication bias assessment for OS with SII (**A**) and CAR (**B**).**Abbreviations:** OS, overall survival; SII, systemic immune-inflammation index; CAR, C-reactive protein-to-albumin ratio.

Sensitivity analysis {#S0003-S2005}
--------------------

The sensitivity analysis indicated that the results of the combined analysis were robust ([Figure 8](#F0008){ref-type="fig"}). Figure 8Sensitivity analysis for OS in SII (**A**) and CAR (**B**).**Abbreviations:** OS, overall survival; SII, systemic immune-inflammation index; CAR, C-reactive protein-to-albumin ratio.

Discussion {#S0004}
==========

Serum biological markers are considered non-invasive and obtained easily in daily clinical practice. Nowadays, many blood-related parameters, including lymphocyte count, plasma fibrinogen and albumin, have been reported as prognostic markers in various malignant tumors.[@CIT0028]--[@CIT0031] But a single blood indicator is often not stable and reliable for they are inevitably susceptible to many other factors. And some comprehensive index based on two or three hematological parameters have been identified, such as platelet to lymphocyte ratio (PLR), monocyte/lymphocyte ratio (MLR) and neutrophil/lymphocyte ratio (NLR), they all showed the potential prognosis prediction in multiple cancers.[@CIT0032]--[@CIT0035]

SII, as a combination of three blood-related factors, neutrophil, platelet, and lymphocyte, was shown to be related with prognosis in upper gastrointestinal (GI) cancers. For example, some researchers have reported that SII might be a useful indicator in predicting survival and clinicopathologic characteristics in patients with gastric cancer.[@CIT0013],[@CIT0036],[@CIT0037] In addition, SII has shown to be superior to PLR, NLR, and MLR as a predictive biomarker in ESCC.[@CIT0014],[@CIT0016] And CAR, based on serum C-reactive protein and albumin, was also revealed the great usefulness as a predictor of survival in various types of tumors, including upper GI cancers. A number of studies have indicated that preoperative high CAR was related with poor prognosis of patients with gastric cancer,[@CIT0038]--[@CIT0041] and also could act as a predictor for short-term complications in gastric cancer patients following gastrectomy.[@CIT0042] And the prognostic values of CAR were also found in the patients with EC.[@CIT0019],[@CIT0020]

SII and CAR, they are both nutrition and inflammation-based indexes although they are based on different serum parameters. The data of these serum factors can be available in routine blood tests, and they are cheap, non-invasive, and easily accessible. And the two indexes could better reflect systemic inflammatory response and also showed better predictive performance in tumors. As yet, until now, there are no studies that comprehensively assess the prognostic and clinicopathological roles of both SII and CAR in cancer of the esophagus. In order to provide new insights that helping understanding the clinical values of SII and CAR in EC patients, a total of twelve original datasets were included to demonstrate the relationship between SII/CAR and clinical relevance in oesophageal cancer. The combined results showed that high pretreatment SII/CAR was significantly associated with worse clinical outcomes in EC patients.

Our study is the first meta-analysis to evaluate the clinical roles of both SII and CAR in EC patients. We found that high pretreatment SII and CAR were closely related to worse clinical outcomes in EC. Both high pretreatment SII and CAR were significantly related to shorter OS in EC patients. And the subgroup meta-analyses also further confirmed the clinical roles of these two indexes in this disease. As for the relationships between SII or CAR and clinical pathological factors in EC, we found that elevated SII and CAR were significantly related with deeper infiltration depth, positive lymph node metastasis, and advanced clinical stage.

Nevertheless, there exist some limitations to our study. First, the total number of included studies were still relatively small and only the articles published in English were searched. Second, the included studies conducted in Asian countries are the majority, which might entail the preferences of the population. Third, most of the studies focused on the prognostic roles of these two indexes on ESCC, as the difference in the pathology of EAC, their prognosis prediction on EAC need further validated. Fourth, there were a diversity of cut-off values that were used to divide the patients into high and low SII/CAR groups. Additionally, many other factors, such as postoperative treatment, tumor stage, they could also affect the survival time of the patients.

In conclusion, our study provides clear evidence that both SII and CAR are correlated with clinical outcomes in EC and could be used as a noninvasive prognostic marker for this disease. In this meta-analysis, the cut-off values for SII (462) and CAR (0.277) are recommended that would be useful for predicting outcomes. Given the limitations mentioned, further larger multi-center studies are required to further confirm our findings.
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Table S1Relevant data of clinicopathologic characteristics for SII and CAR in EC patientsSIICARhistological gradehistological gradePoorly/undifferentiatedWell/ModeratePoorly/undifferentiatedWell/ModerateStudyHigh SIILow SIIHigh SIILow SIIStudyHigh CARLow CARHigh CARLow CARGeng Y, 2016[@CIT0014]306114357139Wei XL, 2015[@CIT0022]669381183Feng JF, 2017[@CIT0016]431517466Xu XL, 2015[@CIT0023]236264318Wang L, 2017[@CIT0019]46816786Ishibashi Y, 2018[@CIT0020]1376261Ishibashi Y, 2018[@CIT0020]1285865Yu X, 2018[@CIT0027]21316444Zhang H, 2018[@CIT0021]7737328213infiltration depthinfiltration depthT 3-4T0-2T 3-4T1-2StudyHigh SIILow SIIHigh SIILow SIIStudyHigh CARLow CARHigh CARLow CARGeng Y, 2016[@CIT0014]377106286147Wei XL, 2015[@CIT0022]881742787Wang L, 2017[@CIT0019]75703897Xu XL, 2015[@CIT0023]742861182Ishibashi Y, 2018[@CIT0020]52311842Ishibashi Y, 2018[@CIT0020]57261842Zhang H, 2018[@CIT0021]3281737777Kunizaki M, 2018[@CIT0026]34291736lymph node metastasislymph node metastasisStudyLNM +LNM -LNM +LNM -High CARLow CARGeng Y, 2016[@CIT0014]341322103150StudyLNM +LNM -LNM +LNM -Wang L, 2017[@CIT0019]654858109Wei XL, 2015[@CIT0022]5449104154Ishibashi Y, 2018[@CIT0020]42284132Xu XL, 2015[@CIT0023]6918228153Zhang H, 2018[@CIT0021]184221105145Ishibashi Y, 2018[@CIT0020]46293731clinical stageclinical stageIII-IV0-IIIII-IVI-IIStudyHigh SIILow SIIHigh SIILow SIIStudyHigh CARLow CARHigh CARLow CARGeng Y, 2016[@CIT0014]27182392171Wei XL, 2015[@CIT0022]9710450172Feng JF, 2017[@CIT0016]1071811063Xu XL, 2015[@CIT0023]6619721184Wang L, 2017[@CIT0019]554658121Ishibashi Y, 2018[@CIT0020]47302838Ishibashi Y, 2018[@CIT0020]43342739Kunizaki M, 2018[@CIT0026]36291536Zhang H, 2018[@CIT0021]253117152133[^4] Table S2Study quality of all included cohort studies in the meta-analysisStudy \[Reference\]\*Hypothesis and/or objective(s) statedTumor stage clearly describedClear description of eligibility criteriaPatients with inflammatory disease or coagulation disorders excludedPredictors and outcome(s) clearly predefinedConfounders considered in multivariate analysisFollow-up period reported and long enough for outcomes to occurBias and limitations consideredQuality score\
(0 − 8)SIIGeng Y, 2016[@CIT0014]yesyesyesnonoyesyesyes6Feng JF, 2017[@CIT0016]yesyesyesyesnoyesyesyes7Wang L, 2017[@CIT0019]yesyesyesyesyesyesnoyes7Ishibashi Y, 2018[@CIT0020]yesyesnonoyesyesyesyes6Zhang H, 2018[@CIT0021]yesyesyesyesyesyesyesyes8CARWei XL, 2015[@CIT0022]yesyesyesyesyesyesyesyes8Xu XL, 2015[@CIT0023]yesyesyesyesyesyesyesyes8Otowa Y, 2017[@CIT0024]yesyesyesnoyesyesyesyes7Jomrich G, 2017[@CIT0025]yesyesyesyesyesyesyesyes8Ishibashi Y, 2018[@CIT0020]yesyesnonoyesyesyesyes6Kunizaki M, 2018[@CIT0026]yesyesnononoyesyesyes5Yu X, 2018[@CIT0027]yesyesyesyesyesyesyesyes8[^5]

**Supplementary File 1**. Literature search strategy in PUBMED

((((C-reactive\[All Fields\] AND protein-to-albumin\[All Fields\] AND ("Ratio (Oxf)"\[Journal\] OR "ratio"\[All Fields\])) OR ("automobiles"\[MeSH Terms\] OR "automobiles"\[All Fields\] OR "car"\[All Fields\])) OR (("c-reactive protein"\[MeSH Terms\] OR ("c-reactive"\[All Fields\] AND "protein"\[All Fields\]) OR "c-reactive protein"\[All Fields\] OR "c reactive protein"\[All Fields\]) AND ("albumins"\[MeSH Terms\] OR "albumins"\[All Fields\] OR "albumin"\[All Fields\]))) OR ((systemic\[All Fields\] AND immune-inflammation\[All Fields\] AND ("abstracting and indexing as topic"\[MeSH Terms\] OR ("abstracting"\[All Fields\] AND "indexing"\[All Fields\] AND "topic"\[All Fields\]) OR "abstracting and indexing as topic"\[All Fields\] OR "index"\[All Fields\])) OR ("Stat Interface"\[Journal\] OR "sii"\[All Fields\]))) AND (((("carcinoma"\[MeSH Terms\] OR "carcinoma"\[All Fields\]) OR ("neoplasms"\[MeSH Terms\] OR "neoplasms"\[All Fields\] OR "cancer"\[All Fields\])) OR ("tumour"\[All Fields\] OR "neoplasms"\[MeSH Terms\] OR "neoplasms"\[All Fields\] OR "tumor"\[All Fields\])) AND esophageal\[All Fields\]) AND ("0001/01/01"\[PDAT\]: "2018/09/01"\[PDAT\]) AND ("loattrfull text"\[sb\] AND English\[lang\])

[^1]: **Abbreviations:** R, retrospective; ESCC, esophageal squamous cell carcinoma; EAC, esophageal carcinoma; OS, overall survival; CSS, cancer-specific survival; MVA, multivariate analysis. ROC, receiver operating characteristic curve; NA, not available.

[^2]: **Abbreviations:** ESCC, esophageal squamous cell carcinoma; HR, hazard ratio; 95%CI, 95% confidence interval; NS: not significant.

[^3]: **Abbreviations:** ESCC, esophageal squamous cell carcinoma; HR, hazard ratio; 95%CI, 95% confidence interval; NS: not significant.

[^4]: **Abbreviations:** SII, systemic immune-inflammation index; CAR, C-reactive protein-to-albumin ratio; EC, esophageal cancer; LNM, lymph node metastasis.

[^5]: **Abbreviations:** SII, systemic immune-inflammation index; CAR, C-reactive protein-to-albumin ratio.
